Cargando…

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?

Detalles Bibliográficos
Autor principal:	Bonin, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563122/ https://www.ncbi.nlm.nih.gov/pubmed/26425673 http://dx.doi.org/10.1016/j.ebiom.2015.06.011

Ejemplares similares

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
por: Taal, B G, et al.
Publicado: (2001)

A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
por: Baars, A, et al.
Publicado: (2002)

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
por: Schippinger, W, et al.
Publicado: (2005)

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer
por: van den Broek, Evert, et al.
Publicado: (2018)

TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients
por: Fariña-Sarasqueta, A., et al.
Publicado: (2010)

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
por: Donada, Marisa, et al.
Publicado: (2013)

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients
por: Kandioler, Daniela, et al.
Publicado: (2015)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
por: Zunder, Stéphanie M., et al.
Publicado: (2018)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2019)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy
por: Chen, Jian, et al.
Publicado: (2014)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
por: Buhl, Ida Kappel, et al.
Publicado: (2016)

PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
por: Wang, Huanan, et al.
Publicado: (2015)

Expression of p21(WAF1) in Astler–Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy
por: Sulzyc-Bielicka, Violetta, et al.
Publicado: (2011)

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
por: Munster, Pamela N, et al.
Publicado: (2001)

Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers
por: Ishida, Kazushige, et al.
Publicado: (2012)

Predictive values of sex and tumour site for survival benefit from 5FU in colorectal cancer
por: Iacopetta, B
Publicado: (2002)

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
por: Lee, Mok-Won, et al.
Publicado: (2021)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
por: Mochizuki, I, et al.
Publicado: (2012)

First Case of Topical 5-FU Therapy for Cutaneous Metastasis in a Patient with Colon Cancer
por: Ahmed, Gulrayz, et al.
Publicado: (2020)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
por: Cassidy, J, et al.
Publicado: (2006)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer
por: Zheng, Peng, et al.
Publicado: (2022)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden
por: Egger, Michael E.
Publicado: (2023)

Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer
por: Liu, Qi, et al.
Publicado: (2019)

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
por: Jeong, Woon Kyung, et al.
Publicado: (2015)

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy
por: Wehler, Thomas C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g6vh2fuhk8s25maepnp2ramuis